Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIFC NASDAQ:BMEA NASDAQ:CELU NASDAQ:CUE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.97-1.9%$1.17$0.73▼$10.95$123.53M1.693.51 million shs1.27 million shsBMEABiomea Fusion$1.63-0.3%$1.54$0.87▼$3.08$117.49M-0.321.41 million shs531,885 shsCELUCelularity$0.89-1.6%$1.21$0.88▼$4.35$25.75M0.44141,675 shs53,849 shsCUECue Biopharma$36.28+1.5%$254.22$4.97▼$41.42$117.40M2.37531,144 shs77,815 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma+4.21%+12.88%-10.00%-41.76%-82.54%BMEABiomea Fusion+1.87%+19.85%-14.21%+33.61%-2.69%CELUCelularity-2.42%-2.87%-34.71%-30.19%-45.66%CUECue Biopharma+5.15%+142.40%-78.91%-87.60%-94.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.97-1.9%$1.17$0.73▼$10.95$123.53M1.693.51 million shs1.27 million shsBMEABiomea Fusion$1.63-0.3%$1.54$0.87▼$3.08$117.49M-0.321.41 million shs531,885 shsCELUCelularity$0.89-1.6%$1.21$0.88▼$4.35$25.75M0.44141,675 shs53,849 shsCUECue Biopharma$36.28+1.5%$254.22$4.97▼$41.42$117.40M2.37531,144 shs77,815 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma+4.21%+12.88%-10.00%-41.76%-82.54%BMEABiomea Fusion+1.87%+19.85%-14.21%+33.61%-2.69%CELUCelularity-2.42%-2.87%-34.71%-30.19%-45.66%CUECue Biopharma+5.15%+142.40%-78.91%-87.60%-94.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIFCALT5 Sigma 1.00SellN/AN/ABMEABiomea Fusion 2.89Moderate Buy$8.29409.89% UpsideCELUCelularity 2.00Hold$6.00571.89% UpsideCUECue Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CELU, CUE, BMEA, and AIFC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform5/5/2026BMEABiomea Fusion Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.004/28/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/20/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.003/27/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $7.003/25/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIFCALT5 Sigma$24.84M4.97N/AN/A$9.07 per share0.11BMEABiomea FusionN/AN/AN/AN/A$0.42 per shareN/ACELUCelularity$26.55M0.97N/AN/A$0.37 per share2.41CUECue Biopharma$27.47M4.28N/AN/A$10.08 per share3.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIFCALT5 Sigma-$344.51MN/AN/AN/AN/A-1,386.90%-50.52%-45.05%N/ABMEABiomea Fusion-$61.80M-$1.31N/AN/AN/AN/A-305.60%-128.09%N/ACELUCelularity-$57.89M-$3.33N/AN/AN/A-198.75%N/A-65.03%5/8/2026 (Estimated)CUECue Biopharma-$26.60M-$9.61N/AN/AN/A-96.85%-165.19%-77.77%N/ALatest CELU, CUE, BMEA, and AIFC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q4 2025CELUCelularityN/A-$0.85N/A-$0.85N/A$4.10 million4/11/2026Q4 2025AIFCALT5 SigmaN/A-$6.19N/A-$6.19N/A$5.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIFCALT5 SigmaN/AN/AN/AN/AN/ABMEABiomea FusionN/AN/AN/AN/AN/ACELUCelularityN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIFCALT5 Sigma0.010.570.57BMEABiomea FusionN/A5.235.23CELUCelularityN/A0.160.12CUECue BiopharmaN/A2.742.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIFCALT5 Sigma6.27%BMEABiomea Fusion96.72%CELUCelularity19.02%CUECue Biopharma35.04%Insider OwnershipCompanyInsider OwnershipAIFCALT5 Sigma0.21%BMEABiomea Fusion18.42%CELUCelularity17.30%CUECue Biopharma1.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIFCALT5 Sigma170127.17 million126.90 millionN/ABMEABiomea Fusion5072.30 million58.98 millionOptionableCELUCelularity22028.84 million23.85 millionOptionableCUECue Biopharma603.24 million3.18 millionOptionableCELU, CUE, BMEA, and AIFC HeadlinesRecent News About These CompaniesChutes & Ladders—Biopharma veteran takes her CEO Cue1 hour ago | fiercebiotech.comFCue Biopharma Grants Inducement Equity Awards to New Executive and EmployeesMay 7 at 7:31 PM | quiverquant.comQCue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7 at 7:15 PM | manilatimes.netMCue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7 at 7:07 PM | globenewswire.comCue Biopharma (NASDAQ:CUE) Downgraded to Buy Rating by Wall Street ZenMay 3, 2026 | marketbeat.comCUE stock jumps over 100% after hours — what’s driving the rally?May 1, 2026 | msn.comCue Biopharma Names Lin as CEO, Secures Exclusive License Agreement with Ascendant Health SciencesMay 1, 2026 | marketwatch.comCue Biopharma Announces $30 Million PIPE Financing Agreement to Advance Clinical PipelineApril 30, 2026 | quiverquant.comQCue Biopharma Announces $30 Million Private PlacementApril 30, 2026 | globenewswire.comCue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE AntibodyApril 30, 2026 | globenewswire.comCue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage CompanyApril 30, 2026 | globenewswire.comCue Biopharma (CUE) price target increased by 2,900.00% to 122.40April 28, 2026 | msn.comCue Biopharma (NASDAQ:CUE) Raised to Strong-Buy at Wall Street ZenApril 25, 2026 | marketbeat.comCue Biopharma (NASDAQ:CUE) Shares Gap Down - Here's WhyApril 24, 2026 | marketbeat.comWhat's behind the drop in Cue Biopharma stock today?April 22, 2026 | msn.comCue Biopharma’s Nasdaq Move Signals Strategic Share RealignmentApril 22, 2026 | kalkinemedia.comKWhat's Behind The Drop In Cue Biopharma Stock Today?April 22, 2026 | benzinga.comCue Biopharma Announces 1-for-30 Reverse Stock SplitApril 22, 2026 | tipranks.comCue Biopharma, Inc. Announces 1-for-30 Reverse Stock Split Effective April 23, 2026April 22, 2026 | quiverquant.comQCue Biopharma Announces 1-for-30 Reverse Stock SplitApril 22, 2026 | globenewswire.com10 Unstoppable Stocks That Could Double Your MoneyApril 20, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELU, CUE, BMEA, and AIFC Company DescriptionsALT5 Sigma NASDAQ:AIFC$0.97 -0.02 (-1.88%) As of 11:06 AM EasternALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Biomea Fusion NASDAQ:BMEA$1.62 -0.01 (-0.31%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Celularity NASDAQ:CELU$0.89 -0.01 (-1.60%) As of 11:25 AM Eastern This is a fair market value price provided by Massive. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Cue Biopharma NASDAQ:CUE$36.28 +0.55 (+1.54%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
